Design and evaluation of sulfadiazine derivatives as potent dual inhibitors of EGFR<sup>WT</sup> and EGFR<sup>T790M</sup>: integrating biological, molecular docking, and ADMET analysis-Reference-Cited by-同舟云学术

Design and evaluation of sulfadiazine derivatives as potent dual inhibitors of EGFR^WT and EGFR^T790M: integrating biological, molecular docking, and ADMET analysis

Published:2024 Issue:39 Volume:14 Page:28608-28625
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Abd El-Lateef Hany M.¹²,Ezelarab Hend A. A.³^ORCID,Ali Ali M.²,Alsaggaf Azhaar T.⁴,Mahdi Wael A.⁵,Alshehri Sultan⁵^ORCID,El Hamd Mohamed A.⁶⁷^ORCID,Aboelez Moustafa O.⁸^ORCID

Affiliation:

1. Department of Chemistry, College of Science, King Faisal University, Al-Ahsa 31982, Saudi Arabia

2. Department of Chemistry, Faculty of Science, Sohag 82524, Egypt

3. Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, 61519-Minia, Egypt

4. Department of Chemistry, Taibah University, Madinah, Saudi Arabia

5. Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia

6. Department of Pharmaceutical Chemistry, College of Pharmacy, Shaqra University, Shaqra 11961, Saudi Arabia

7. Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, South Valley University, Qena 83523, Egypt

8. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sohag University, Sohag, Egypt

Abstract

A series of derivatives (5–14) were synthesized through the diazotization of sulfadiazine with active methylene compounds.

Funder

Shaqra University

Deanship of Scientific Research, King Faisal University

King Saud University

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/RA/D4RA04165H

Reference62 articles.

1. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer

2. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations

3. Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)

4. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

5. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors